102
Participants
Start Date
May 31, 2007
Primary Completion Date
April 30, 2016
Study Completion Date
April 30, 2016
Benazepril
Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
Valsartan
Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
Benazepril/Valsartan
Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
Clinical Department of Endocrinology, Diabetes and Metabolic Diseases University Medical Centre Ljubljana, Ljubljana
"Hospital Azienda Ospedaliera Ospedali Riuniti di Bergamo - Unit of Diabetology", Bergamo
"Clinical Research Center for Rare Diseases Aldo e Cele Daccò", Ranica
"Hospital Bolognini", Seriate
"Hospital S.Marta e S.Venera", Acireale
"Hospital Vittorio Emanuele-Ferrarotto-Santo Bambino", Catania
"Hospital Casa Sollievo della Sofferenza - Unit of Nephrology", San Giovanni Rotondo
"University Federico II", Napoli
"Hospital G:Mazzini", Teramo
IRCCS San Raffaele - Unit of General Medicine, Milan
"Hospital Azienda Ospedaliera di Parma - Unit of Nephrology", Parma
"Hospital Azienda Ospedaliera di Treviglio e Caravaggio - Ambulatory of Ponte San Pietro", Ponte San Pietro
"Hospital Azienda Ospedaliera di Treviglio e Caravaggio Unit of Diabetology and Metabolic Diseases", Romano di Lombardia
University - AUSL 1 - Institute of Medical Pathology, Sassari
"Hospital Azienda Ospedaliera di Treviglio-CaravaggioUnit of Diabetology and Metabolic Diseases", Treviglio
Agenzia Italiana del Farmaco
OTHER_GOV
Mario Negri Institute for Pharmacological Research
OTHER